Alexza teams up with Biovail in North America for anti-agitation therapy
This article was originally published in Scrip
Executive Summary
Alexza Pharmaceuticals has entered a $130 million collaboration to develop and commercialise its inhaled anti-agitation therapy, AZ-004 (Staccato loxapine), in North America, with a Biovail subsidiary.